The UK regulations prohibit the advertising of prescription drugs to the public, but critics found the Medicines and Healthcare Products Regulatory Agency (MHRA) has not issued a single sanction for prescription drugs in the last five years. Critics argue that this lack of enforcement fails patients who may be exposed to the adverse effects of weight loss drugs. Additionally, online promotion of prescription-only drugs is a growing concern, with loopholes in regulation and poor monitoring systems. Critics are calling for stronger enforcement and regulation to protect the public from illegal advertisements and the potential risks associated with prescription drugs.
Source link
Lax oversight of semaglutide advertising could harm patients, warn critics
